Drugs / Adjuvanted, trivalent subunit influenza vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02126761 Comparator | Jun 2014 → Nov 2015 | influenza | Seqirus | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adjuvanted, trivalent subunit influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02126761 ↗ |
| Known as | aTIV | “In this study, the safety and immunogenicity of the current formulation of aTIV will be compared to aTIV-modified formulations in which the dosage of the MF59 adjuvant will be...” NCT02126761 ↗ |
| Modality | Vaccine | “Adjuvanted, trivalent subunit influenza vaccine” NCT02126761 ↗ |